Pfizer Announces Positive Results from Phase 3 AFFINE Study of Haemophilia a Gene Therapy Candidate

Pfizer Announces Positive Results from Phase 3 AFFINE Study of Haemophilia a Gene Therapy Candidate

By, Admin 25 July 2024

Overview

Pfizer Inc. announced positive topline results from the phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe haemophilia A.

AFFINE Study

  • The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment. 
  • Following a single 3e13 vg/kg dose, giroctocogene fitelparvovec demonstrated a statistically significant reduction in mean total ABR compared to the pre-infusion period (1.24 vs 4.73; one-sided p-value=0.0040).

Secondary Endpoints

  • Key secondary endpoints as defined by the trial protocol were met and also demonstrated superiority compared to prophylaxis. 
  • 84% of participants maintained FVIII activity >5% at 15 months post-infusion (one-sided p-value = 0.0086) with the majority of participants having FVIII activity =15%, and the mean treated ABR showed a statistically significant 98.3% reduction from 4.08 in the pre-infusion period to 0.07 post-infusion (from Week 12 up to at least 15 months [15-44 months]; one-sided p-value < 0.0001). 
  • Throughout the study, among all dosed participants, one participant (1.3%) returned to prophylaxis post-infusion.

In the AFFINE study, giroctocogene fitelparvovec was generally well tolerated. Transient elevated FVIII levels =150% were observed in 49.3% of dosed participants, as measured via chromogenic assay, with no impact on efficacy and safety results. Serious adverse events were reported in 15 patients (20%), including 13 events reported by 10 patients (13.3%) assessed as related to treatment. Treatment-related adverse events generally resolved in response to clinical management.

From the University of California 

  • For people living with haemophilia A, the physical and emotional impact of needing to prevent and treat bleeding episodes through frequent IV infusions or injections cannot be underestimated,” said Professor Andrew Leavitt M.D., AFFINE lead investigator, Departments of Laboratory Medicine and Medicine Division of Haematology/Oncology Director, Adult Haemophilia Treatment Center, University of California, San Francisco, CA. 
  • I’m excited by the strength of these positive results from the AFFINE trial that show giroctocogene fitelparvovec was generally well tolerated, and demonstrate the transformative potential of this gene therapy candidate to provide superior bleed protection compared with routine FVIII prophylaxis, while helping relieve the treatment burden for people living with haemophilia A.

Giroctocogene Fitelparvovec

  • Giroctocogene fitelparvovec is a novel, investigational gene therapy that contains a bio-engineered AAV6 capsid and a modified B-domain deleted human coagulation FVIII gene. 
  • The goal of this investigational treatment for people living with haemophilia A is that a single infusion of giroctocogene fitelparvovec may allow them to produce FVIII themselves for an extended period of time, providing bleed protection and reducing the need for routine prophylaxis with intravenous (IV) infusions or injections.

From Pfizer

  • We are very pleased with these positive results from the phase 3 AFFINE study demonstrating the safety and efficacy of our one-time gene therapy candidate for people with haemophilia A,” said James Rusnak, M.D., Ph.D., senior vice president, chief development officer, Internal Medicine and Infectious Diseases, research and development, Pfizer. 
  • We look forward to advancing this latest innovation to help address the medical and treatment burden associated with frequent and time-consuming IV infusions or injections, building on Pfizer’s more than 40-year effort to advance haemophilia treatment.

Phase 3 Study

  • In this phase 3 study, eligible study participants were initially enrolled in a lead-in study (NCT03587116) and upon successful completion, were enrolled into the AFFINE study where they received a one-time 3e13 vg/kg dose of giroctocogene fitelparvovec by IV infusion. 
  • Participants in the AFFINE study were screened with a validated assay designed to identify individuals who test negative for neutralizing antibodies to the gene therapy vector. 
  • Clinical study participants will be evaluated in AFFINE over the course of five years, and up to a total of 15 years as part of a long-term follow-up study.

Giroctocogene Fitelparvovec: FTA

  • Analyses of the full phase 3 dataset from the AFFINE study are ongoing and additional data will be presented at upcoming medical meetings. 
  • Giroctocogene fitelparvovec has been granted Fast Track and Regenerative Medicine Advanced Therapy designations from the US Food and Drug Administration (FDA), as well as Orphan Drug designations in the US and the European Union. 
  • Pfizer will discuss these data with regulatory authorities in the coming months.

FDA Approval for Beqvez

  • Pfizer recently received FDA approval for Beqvez (fidanocogene elaparvovec), its haemophilia B gene therapy. 
  • Beqvez is also approved in Canada and is awaiting a decision from the European Medicines Agency (EMA) following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use in May 2024. 
  • Additionally, regulatory submissions for marstacimab are currently under review by the FDA and the EMA. 
  • Marstacimab is a potential novel subcutaneous therapy being studied for the treatment of people with haemophilia A and B with and without inhibitors. 
  • Pfizer announced the acceptance of the regulatory filings for the without inhibitors cohort in December 2023.

Phase 3 AFFINE Study

  • The phase 3 AFFINE (NCT04370054) study is an open-label, multicenter, single-arm study to evaluate the efficacy and safety of a single infusion of giroctocogene fitelparvovec in adult male participants (n=75 dosed participants) with moderately severe to severe haemophilia A. 
  • Study participants included in the assessments of the key endpoints of the primary efficacy analysis (n=50) completed a minimum six months of routine FVIII replacement prophylaxis therapy during the lead-in study (NCT03587116) providing data to compare with post giroctocogene fitelparvovec treatment.

Primary Endpoint

The primary endpoint measures the total annualized bleeding rate (ABR; spontaneous and traumatic bleedings, treated and untreated) from Week 12 through at least 15 months following treatment with giroctocogene fitelparvovec compared to total ABR on prior FVIII prophylaxis replacement therapy.

Development of Giroctocogene Fitelparvovec

  • Giroctocogene fitelparvovec is being developed as part of a collaboration agreement for the global development and commercialization of gene therapies for haemophilia A between Sangamo Therapeutics and Pfizer. 
  • In late 2019, Sangamo transferred the manufacturing technology and the Investigational New Drug application to Pfizer. 
  • Under the agreement, Pfizer assumed responsibility for pivotal studies, any regulatory activities, and potential global commercialization of giroctocogene fitelparvovec.

Haemophilia

  • Haemophilia is an inherited, rare bleeding disorder that causes people to bleed for longer than normal due to a deficiency of a protein required for normal blood clotting, known as clotting factor VIII (FVIII) in haemophilia A. 
  • The severity of haemophilia is determined by the amount of factor in the blood. 
  • The lower the amount of the factor, the more likely it is that bleeding will occur which can lead to serious health problems.

Haemophilia A

  • Haemophilia A occurs in approximately 25 in every 100,000 male births worldwide. 
  • Approximately 55-75% of males with haemophilia A have a moderate to severe form of the disease. 
  • For people who live with haemophilia A, there is an increased risk of spontaneous bleeding as well as bleeding following injuries or surgery. 
  •  It is a lifelong disease that requires constant monitoring and therapy.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!